Because CBL is a direct target of miR-22-3p and also an E3 ligase of SPRY2, we hypothesize that miR-22-3p may regulate SPRY2 by inhibiting CBL to establish its functional role in HCC development. The gene discussed is SPRY2; the disease is hepatocellular carcinoma.